solderol 1000 j.m. tabletki powlekane
przedsiębiorstwo farmaceutyczne lek-am sp. z o.o. - cholecalciferolum - tabletki powlekane - 1000 j.m.
solderol 30000 j.m. tabletki powlekane
przedsiębiorstwo farmaceutyczne lek-am sp. z o.o. - cholecalciferolum - tabletki powlekane - 30000 j.m.
solderol 7000 j.m. tabletki powlekane
przedsiębiorstwo farmaceutyczne lek-am sp. z o.o. - cholecalciferolum - tabletki powlekane - 7000 j.m.
dekristol 20 000 iu kapsułki miękkie
sun-farm sp. z o.o. - cholecalciferolum - kapsułki miękkie - 20 000 iu
masti veyxym (8 mg + 8 mg + 4 mg + 100 000 iu + 120 mg)/10 g zawiesina dowymieniowa
veyx-pharma gmbh - witamina e + trypsyna + chymotrypsyna + vitaminum a + papainum - zawiesina dowymieniowa - (8 mg + 8 mg + 4 mg + 100 000 iu + 120 mg)/10 g - bydło
devikap 2000 iu kapsułki miękkie
zakłady farmaceutyczne polpharma s.a. - cholecalciferolum - kapsułki miękkie - 2000 iu
devikap 4000 iu kapsułki miękkie
zakłady farmaceutyczne polpharma s.a. - cholecalciferolum - kapsułki miękkie - 4000 iu
devikap 10 000 iu kapsułki miękkie
zakłady farmaceutyczne polpharma s.a. - cholecalciferolum - kapsułki miękkie - 10 000 iu
vigalex bio 1000 iu tabletki
biofarm sp. z o.o. - cholecalciferolum, pulvis - tabletki - 1000 iu
rivaroxaban viatris (previously rivaroxaban mylan)
mylan ireland limited - rywaroksaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - Środki przeciwzakrzepowe - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers. rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery. treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.